We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

QTWO:NYSEQ2 Holdings, Inc. analysis

Data as of Oct 23, 2026 - not real-time

Latest price
$69.39
Risk: medium
6/10Medium risk

Summary

At $69.39, Q2 Holdings, Inc. shows no decisive moving-average alignment, leaving the trend neutral. The last 30 days have gained 14.0%. RSI sits at 80.7, which reads as overbought, and MACD momentum is bullish. Recent trading has carved out support near $54.51 and resistance around $70.19.
The shares look overvalued, trading on 49.2 times earnings above a sector average of 30.0. Analyst price targets sit 9.0% above the current price. Revenue is growing at 12.6% on a 10.9% profit margin.
Risk scores 6 out of 10, which is elevated for this asset class. With 30-day volatility of 33.2%, a beta of 0.29 and a maximum drawdown of 44.2%, position sizing matters here. The wider market backdrop reads extreme greed at 87 on the fear-greed composite.
All three time horizons resolve to hold, carrying 1/10 conviction.

Top market events

  • Looking back on vertical software stocks’ Q2 earnings, we examine this quarter’s best and worst performers,...
  • US Stock Market Information for NASDAQ, NYSE, AMEX
  • Looking back on vertical software stocks’ Q2 earnings, we examine this quarter’s best and worst performers,...

Market outlook

Short term

< 1 year

Neutral

Model confidence2/102 out of 10

Key factors

  • RSI at 80.7 signals overbought conditions
  • Trading above the 200-day average of 54.63
  • MACD momentum is positive

Medium term

1–3 years

Neutral

Model confidence1/101 out of 10

Key factors

  • RSI at 80.7 signals overbought conditions
  • P/E of 49.2 versus sector average of 30.0
  • Trading above the 200-day average of 54.63

Long term

> 3 years

Neutral

Model confidence1/101 out of 10

Key factors

  • P/E of 49.2 versus sector average of 30.0
  • Analyst targets imply +9.0% versus the current price
  • Revenue growth of +12.6%

Key metrics

Financial health

Revenue Growth12.60%
Profit Margin10.87%
P/E Ratio49.2
ROE14.98%
ROA4.53%
Debt/Equity6.36
P/B Ratio6.7
Op. Cash Flow$226.3M
Free Cash Flow$190.3M
Industry P/E30.0

Technical analysis

TrendNeutral
RSI80.7
Support$54.51
Resistance$70.19
MA 20$60.22
MA 50$61.08
MA 200$54.63
MACDBullish
VolumeIncreasing
Fear & Greed Index86.7

Valuation

Fair Value$64.67
Target Price$75.64
Upside/Downside9.01%
GradeOvervalued
TypeGrowth

Risk assessment

Beta0.29
Volatility33.18%
Sector RiskHigh
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.